Fewer than 10% of patients who could benefit from obesity jabs including Wegovy can access them, states the WHO as it publishes its first guidance on the therapies.
Given in excess of 1,000,000,000 individuals worldwide now living with obesity, it is advocating for broader and more equitable access to these injectable treatments.
Per projections, in excess of 2,000,000,000 are projected to be obese by 2030 unless action is taken.
"The new guidelines recognises that excess weight is a lifelong illness that can be addressed with thorough and continuous support," stated the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and logistical bottlenecks are major barriers to widespread availability to the injections that can assist patients in reducing substantial weight, explains the agency.
Skinny Jab Shortage
Despite the current best projected case, the manufacturing of such drugs might only reach about 100 million people – fewer than 10% of those who need them, as stated by the WHO.
The advice encourages nations and manufacturers to expand availability, via measures like voluntary licensing.
The intellectual property rights on semaglutide – the primary ingredient of Novo Nordisk's Wegovy – is set to lapse in multiple nations in 2026.
How Weight-Loss Jabs Operate
These medications imitate a body's own hormone to reduce digestion speed, curb appetite and enhance satiety so users consume fewer calories.
Patients usually begin shedding pounds within a few weeks of beginning the weekly injections.
Studies suggests people may put most of the weight back on after a year of discontinuing the medication, because their usual hunger come back.
To be carrying excess weight elevates your chance for developing medical conditions, like diabetes, cardiovascular issues, stroke, and specific malignancies.
Excess weight concerns people in all nations and was associated with 3.7 million fatalities worldwide in 2024, as per the health agency.
